Delay discounting and e-cigarette use: An investigation in current, former, and never cigarette smokers

Stein, Jeffrey S.; Heckman, Bryan W.; Pope, Derek A.; Perry, Elan S.; Fong, Geoffrey T.; Cummings, K. Michael; Bickel, Warren K.

doi:10.1016/j.drugalcdep.2018.06.034

Cited by 18 publications

(25 citation statements)

References 53 publications

(99 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expressing this value as effective delay 50 (ED 50 ), the delay at which a reward loses 50% of its value, $1000 lost half its value in a mean of 110 days [59]. Among smokers in the general population, the discounting rate is lnk = −4.0 to −2.9 and $1000 loses half of its value in only 18-50 days [60][61][62][63]. While lower discounting rates are, of course, indicative of improved treatment outcomes [35,36,[64][65][66], the lower rates in this study may reflect a selection bias whereby CSs who discounted at higher rates were less likely to agree to attend treatment.…”

Section: Discussionmentioning

confidence: 99%

Tobacco Dependence Treatment in Oncology: Initial Patient Clinical Characteristics and Outcomes from Roswell Park Comprehensive Cancer Center

Sheffer

Stein

Petrucci

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

Despite the importance of smoking cessation to cancer care treatment, historically, few cancer centers have provided treatment for tobacco dependence. To address this gap, the National Cancer Institute (NCI) launched the Cancer Center Cessation Initiative (C3i). As part of this effort, this study examined implementation outcomes in a cohort of cancer survivors (CSs) who smoked cigarettes in the first year of an ongoing process to develop and implement a robust Tobacco Treatment Service at Roswell Park Comprehensive Cancer Center. We provide a comprehensive description of the new tobacco use assessment and referral process, and of the characteristics of cancer survivors who agreed to treatment including traditional tobacco-related psychosocial and cancer treatment-related characteristics and novel characteristics such as delay discounting rates. We also examine characteristic differences among those who agreed to treatment between those who attended and those who did not attend treatment. As the new tobacco assessment was implemented, the number of referrals increased dramatically. The mean number of treatment sessions attended was 4.45 (SD = 2.98) and the six-month point prevalence intention to treat abstinence rate among those who attended was 22.7%. However, only 6.4% agreed to treatment and 4% attended at least one treatment session. A large proportion of cancer survivors who agreed to treatment were women, of older age, of lower socioeconomic status (SES), and who had high levels of depressive symptomology. The findings demonstrate that the implementation of system changes can significantly improve the identification of cancer survivors who use tobacco and are referred to tobacco use treatment. Among those who attend, treatment is effective. However, the findings also suggest that a systematic assessment of barriers to engagement is needed and that cancer survivors may benefit from additional treatment tailoring. We present plans to address these implementation challenges. Systematic electronic medical record (EMR)-sourced referral to tobacco treatment is a powerful tool for reaching cancer survivors who smoke, but more research is needed to determine how to enhance engagement and tailor treatment processes.

show abstract

Section: Discussionmentioning

confidence: 99%

Tobacco Dependence Treatment in Oncology: Initial Patient Clinical Characteristics and Outcomes from Roswell Park Comprehensive Cancer Center

Sheffer

Stein

Petrucci

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Investigating potential moderators of bundling effects in future research may help to explain observed heterogeneity. For example, studies may be designed to examine interactions between choice bundling and various behavioral, psychological, and sociodemographic factors that are commonly associated with delay discounting [e.g., cigarette smoking; 38,45] or moderate effects of interventions that reduce delay discounting [e.g., working memory; 20,46]. The present study had limited statistical power to conduct such analyses because recruitment of a general sample yields relatively few cigarette smokers or members of other clinical populations.…”

Section: Choice Bundling and Additive Hyperbolic Delay Discountingmentioning

confidence: 99%

“…Three additional questions were specific to the choice tasks. Because the five-trial task does not allow use of standardized diagnostic criteria to assess orderliness of obtained data [e.g., 40], these quality control questions were appended to the five-trial, adjusting-delay task, as has been done previously [12,38]. Specifically, in each of three bundle-size conditions, a sixth trial asked participants to choose between $500 now and $1000 now.…”

Section: Plos Onementioning

confidence: 99%

“…Estimates of discounting from this task also show strong concordance with those from the more common, but also more time-consuming, adjusting-amount task (e.g., r=.67-.86 for monetary rewards; [20,39,49]). Moreover, both tasks are sensitive to the same experimental manipulations [12,20,39,50,51] and cross-sectional associations with maladaptive health behavior [12,38,52].…”

Section: Choice Bundling and Additive Hyperbolic Delay Discountingmentioning

confidence: 99%

See 1 more Smart Citation

Choice bundling, unpacked: Observed and predicted effects on intertemporal choice in an additive model of hyperbolic delay discounting

Stein

Madden

2021

PLoS ONE

Self Cite

View full text Add to dashboard Cite

One method known to increase preference for larger, later rewards (LLRs) over smaller, sooner rewards (SSRs) is choice bundling, in which a single choice produces a series of repeating consequences over time. The present study examined whether effects of choice bundling on preference for LLRs: (1) increase with the number of rewards in the bundle (i.e., bundle size); (2) are independent of differences in reward magnitude between conditions; and (3) accord with predictions of an additive model of hyperbolic delay discounting, in which the value of a bundle of rewards can be expressed as the summed discounted value of all rewards in that bundle. Participants (N = 252) completed a choice task to assess valuation of monetary LLRs at bundle sizes of 1 (control), 3, and 9 rewards per choice (ascending/descending order counterbalanced). To control for the magnitude effect, the total reward amounts were held constant across conditions. Choice bundling significantly increased LLR preference (p < .001), with the largest effect observed at the largest bundle size. The descending bundle-size order produced significantly greater LLR preference than the ascending order (p < .05), although order did not significantly interact with bundle size. Difference scores between observed measures and those predicted by an additive model of hyperbolic discounting were small and not significantly different than zero, but were not equivalent to zero. Future research should investigate the clinical utility of choice bundling for reducing the maladaptive health behavior (e.g., substance use) with which delay discounting is associated.

show abstract

“…A meta-analysis found that reduced delay discounting in smokers predicted reduced future smoking and better quit rates [73]. Past smokers have been found to discount less steeply than current smokers [74], and this finding has recently been extended to e-cigarette use [75]. Delay discounting seems to follow an inverted-U trajectory following cessation, with increased discounting in early abstinence that is attenuated with prolonged abstinence.…”

Section: Introductionmentioning

confidence: 99%

Neurobiological Considerations for Tobacco Use Disorder

Chawla

Garrison

2018

Curr Behav Neurosci Rep

View full text Add to dashboard Cite

Purpose of review: Neurobiological studies of tobacco/nicotine use examining genetic, molecular, functional, and behavioral correlates have improved our understanding of nicotine/tobacco dependence and have informed treatment. Recent work extending previously established findings and reporting novel methodologies and discoveries in preclinical and human studies are reviewed. Recent findings: Recent work in preclinical models has focused on the differential roles of nicotinic receptor subtypes and nicotine’s effects on neural systems beyond cortico-striatal dopaminergic pathways, and utilizing advanced methodologies such as pharmacogenetics, optogenetics and rodent fMRI to identify targets for treatment. Likewise, human neuroimaging studies have identified molecular and functional dynamic shifts associated with tobacco/nicotine use that further inform treatment. Summary: Nicotine/tobacco use is associated with widespread neural adaptations that are persistent and function to maintain addiction. The continued identification of genetic, molecular, neural, and behavioral endophenotypes related to nicotine/tobacco use, dependence, and addiction will facilitate the development and delivery of personalized treatment.

show abstract

Delay discounting and e-cigarette use: An investigation in current, former, and never cigarette smokers

Abstract: The smaller effect size for the association between delay discounting and current EC use, relative to current cigarette use, suggests that public perception of ECs as a safer alternative to cigarettes attenuates the role of delay discounting in decisions to use ECs.

Cited by 18 publications

References 53 publications

Tobacco Dependence Treatment in Oncology: Initial Patient Clinical Characteristics and Outcomes from Roswell Park Comprehensive Cancer Center

Tobacco Dependence Treatment in Oncology: Initial Patient Clinical Characteristics and Outcomes from Roswell Park Comprehensive Cancer Center

Choice bundling, unpacked: Observed and predicted effects on intertemporal choice in an additive model of hyperbolic delay discounting

Neurobiological Considerations for Tobacco Use Disorder

Contact Info

Product

Resources

About